Janusz Jaworski

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)

Christopher J Edwards, Francisco J. Blanco, Jeffrey Crowley et al. · Annals of the Rheumatic Diseases · 2016 · 283 citations · Full text

Medicine, Dermatology, Pharmacotherapy +15

Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study

Dae‐Hyun Yoo, Nenad Prodanović, Janusz Jaworski et al. · Annals of the Rheumatic Diseases · 2016 · 280 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study

Won Park, Dae‐Hyun Yoo, Janusz Jaworski et al. · Arthritis Research & Therapy · 2016 · 139 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +9

Phase <scp>III</scp> Randomized Study of <scp>SB</scp>5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis

Michael E. Weinblatt, Asta Baranauskaitė, Jaroslaw Niebrzydowski et al. · Arthritis & Rheumatology · 2017 · 133 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis

Michael E. Weinblatt, Asta Baranauskaitė, Eva Dokoupilová et al. · Arthritis & Rheumatology · 2018 · 116 citations · Full text

Life Sciences, Clinical Sciences, Pharmacotherapy +17